Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRD003
- Development stage
- Preclinical
- Lead developer
- PRD Therapeutics
- Modality
- Small Molecules
01
Overview
PRD003 is a selective small molecule inhibitor of sterol O-acyltransferase 2 (SOAT2) currently in development by PRD Therapeutics. SOAT2 is an enzyme primarily expressed in the liver and intestine that catalyzes the esterification of cholesterol. By inhibiting SOAT2, PRD003 aims to modulate cholesterol esterification and reduce the accumulation of cholesterol esters, which is a hallmark of Lysosomal Acid Lipase Deficiency (LAL-D). The drug is currently in the lead optimization stage and is being investigated for the treatment of LAL-D and other rare dyslipidemia-associated diseases.
Beyond the preview
Go deeper on PRD003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRD003.